Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 5MB, 224 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 10 results:
Author Title [ Type(Desc)] Year
Filters: Author is Driessen, J. H.  [Clear All Filters]
Journal Article
J. H. Driessen, Henry, R. M., van Onzenoort, H. A., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G., and de Vries, F., “Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis”, Calcif Tissue Int, vol. 97, pp. 104-12, 2015.
J. M. Wijnands, van Durme, C. M., Driessen, J. H., Boonen, A., Klop, C., Leufkens, B., Cooper, C., Stehouwer, C. D., and de Vries, F., “Individuals With Type 2 Diabetes Mellitus Are at an Increased Risk of Gout But This Is Not Due to Diabetes: A Population-Based Cohort Study”, Medicine (Baltimore), vol. 94, p. e1358, 2015.
M. E. Goossens, Buntinx, F., Zeegers, M. P., Driessen, J. H., De Bruin, M. L., and de Vries, F., “Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients”, Br J Clin Pharmacol, vol. 80, pp. 1464-72, 2015.
J. H. Driessen, van den Bergh, J. P., van Onzenoort, H. A., Henry, R. M., Leufkens, H. G., and de Vries, F., “Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 421-428, 2017.
D. C. Braeken, Rohde, G. G., Franssen, F. M., Driessen, J. H., van Staa, T. P., Souverein, P. C., Wouters, E. F., and de Vries, F., “Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom”, Int J Chron Obstruct Pulmon Dis, vol. 12, pp. 2425-2432, 2017.
J. van Dalem, Brouwers, M. C., Stehouwer, C. D., Krings, A., Leufkens, H. G., Driessen, J. H., de Vries, F., and Burden, A. M., “Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study”, Bmj, vol. 354, p. i3625, 2016.
J. H. Driessen, van Onzenoort, H. A., Henry, R. M., Lalmohamed, A., van den Bergh, J. P., Neef, C., Leufkens, H. G., and de Vries, F., “Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture”, Bone, vol. 68, pp. 124-30, 2014.
W. R. der Zanden, de Vries, F., Lalmohamed, A., Driessen, J. H., de Boer, A., Rohde, G., Neef, C., and C. Heijer, den, “Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study”, PLoS One, vol. 10, p. e0139367, 2015.
L. M. Knapen, de Jong, R. G., Driessen, J. H., Keulemans, Y. C., van Erp, N. P., De Bruin, M. L., Leufkens, H. G., Croes, S., and de Vries, F., “Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 401-411, 2017.
L. M. Knapen, van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G., Croes, S., Neef, C., de Vries, F., and Driessen, J. H., “Use of incretin agents and risk of pancreatic cancer: a population-based cohort study”, Diabetes Obes Metab, vol. 18, pp. 258-65, 2016.
[Page last reviewed 8 March 2021]